NCT00316849View on ClinicalTrials.gov

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2010

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
Interventions
OTHER

pharmacological study

PROCEDURE

adjuvant therapy

RADIATION

3-dimensional conformal radiation therapy

RADIATION

intensity-modulated radiation therapy

DRUG

temsirolimus

Given IV

DRUG

temozolomide

Given orally

Trial Locations (11)

50307

Mercy Capitol, Des Moines

50309

Iowa Methodist Medical Center, Des Moines

Iowa Oncology Research Association CCOP, Des Moines

Medical Oncology and Hematology Associates-Des Moines, Des Moines

50314

Medical Oncology and Hematology Associates, Des Moines

Mercy Medical Center - Des Moines, Des Moines

50316

Iowa Lutheran Hospital, Des Moines

50325

Medical Oncology and Hematology Associates-West Des Moines, Clive

55905

Mayo Clinic, Rochester

58201

Altru Cancer Center, Grand Forks

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter